viewTissue Regenix Group PLC
Tissue Regenix MD says the company is at an "exciting period"
Antony Odell, MD of Tissue Regenix (LON:TRX), explains to Proactiveinvestors that the company is at an "exciting period" in its development and, because it is a medical devices company, it is a "lower risk, lower cost and more predictable" business model than a biotech business. Antony also explains that the real benefits of the TRX patented technology are the opportunities from "big unmet needs" in the aging population.
Quick facts: Tissue Regenix Group PLC
Price: 0.35 GBX
AIM:TRX
Market: AIM
Market Cap: £24.62 m
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Tissue Regenix Group PLC named herein, including the promotion by the Company of Tissue Regenix Group PLC in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HEREMost read
Director Interviews
CytoDyn CEO calls Citron Research report 'false', updates on coronavirus...
4 days ago
Health
Coronavirus: China approves vaccine for military use, global deaths reach...
6 days, 4 hours ago
